BACKGROUND: The optimal ablation approach for patients with persistent atrial fibrillation (AF) remains unknown. In particular, it is unclear if pulmonary vein (PV) antral isolation (PVI) is sufficient as a lone strategy for persistent AF. Furthermore, if additional substrate ablation is to be added, the ideal approach to substrate ablation is yet to be determined. OBJECTIVE: The aim of this study is to determine the optimal strategy of catheter ablation of persistent AF by comparing the efficacy of 3 strategies: PVI vs PVI plus complex fractionated electrogram (CFE) ablation (PVI + CFE) vs PVI plus linear ablation (PVI + Lines). STUDY DESIGN: The STAR AF II study (ClinicalTrials.gov NCT01203748) is a prospective, multicenter, randomized trial with a blinded assessment of outcomes. A total of 549 patients will be randomized in a 1:4:4 fashion to one of the investigation arms: PVI, PVI + CFE, and PVI + Lines, respectively. Patients undergoing a first-time ablation procedure for symptomatic, persistent AF that is refractory to at least 1 antiarrhythmic medication will be included. Persistent AF will be defined as a sustained episode lasting >7 days and <3 years. Patients with a left atrial parasternal size ≥60 mm will be excluded. The primary end point is freedom from documented AF >30 seconds at 18 months after 1 or 2 ablation procedures with or without antiarrhythmic medications. CONCLUSIONS: The STAR AF II study is a randomized trial designed to evaluate the optimal approach for catheter ablation of persistent AF.
RCT Entities:
BACKGROUND: The optimal ablation approach for patients with persistent atrial fibrillation (AF) remains unknown. In particular, it is unclear if pulmonary vein (PV) antral isolation (PVI) is sufficient as a lone strategy for persistent AF. Furthermore, if additional substrate ablation is to be added, the ideal approach to substrate ablation is yet to be determined. OBJECTIVE: The aim of this study is to determine the optimal strategy of catheter ablation of persistent AF by comparing the efficacy of 3 strategies: PVI vs PVI plus complex fractionated electrogram (CFE) ablation (PVI + CFE) vs PVI plus linear ablation (PVI + Lines). STUDY DESIGN: The STAR AF II study (ClinicalTrials.gov NCT01203748) is a prospective, multicenter, randomized trial with a blinded assessment of outcomes. A total of 549 patients will be randomized in a 1:4:4 fashion to one of the investigation arms: PVI, PVI + CFE, and PVI + Lines, respectively. Patients undergoing a first-time ablation procedure for symptomatic, persistent AF that is refractory to at least 1 antiarrhythmic medication will be included. Persistent AF will be defined as a sustained episode lasting >7 days and <3 years. Patients with a left atrial parasternal size ≥60 mm will be excluded. The primary end point is freedom from documented AF >30 seconds at 18 months after 1 or 2 ablation procedures with or without antiarrhythmic medications. CONCLUSIONS: The STAR AF II study is a randomized trial designed to evaluate the optimal approach for catheter ablation of persistent AF.
Authors: A Ambrogelly; S Kamtekar; A Sauerwald; B Ruan; D Tumbula-Hansen; D Kennedy; I Ahel; D Söll Journal: Cell Mol Life Sci Date: 2004-10 Impact factor: 9.261
Authors: Hugo Enrique Coutiño; Carlo de Asmundis; Giacomo Mugnai; Darragh Moran; Valentina De Regibus; Erwin Ströker; Ken Takarada; Diego Ruggiero; Rajin Choudhury; Stefan Beckers; Carla Van Gompel; Jan Poelaert; Saverio Iacopino; Pasquale Filannino; Pedro Brugada; Gian-Battista Chierchia Journal: J Interv Card Electrophysiol Date: 2016-08-25 Impact factor: 1.900
Authors: Irfan M Khurram; Mohammadali Habibi; Esra Gucuk Ipek; Jonathan Chrispin; Eunice Yang; Kotaro Fukumoto; Jane Dewire; David D Spragg; Joseph E Marine; Ronald D Berger; Hiroshi Ashikaga; Jack Rickard; Yiyi Zhang; Vadim Zipunnikov; Stefan L Zimmerman; Hugh Calkins; Saman Nazarian Journal: JACC Cardiovasc Imaging Date: 2016-01-06
Authors: Edward J Ciaccio; Angelo B Biviano; Alok Gambhir; Jason T Jacobson; Hasan Garan Journal: Pacing Clin Electrophysiol Date: 2013-08-26 Impact factor: 1.976